Denali Therapeutics Inc

For the period ended Dec 31, 2023. Filed Feb 28, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Feb 28, 2024

DNLI$20.33+1.3%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Annual Report on Form 10-K

TABLE OF CONTENTS

Page
PART I
Item 1.	Business	6
Item 1A.	Risk Factors	57
Item 1B.	Unresolved Staff Comments	121
Item 2.	Properties	123
Item 3.	Legal Proceedings	123
Item 4.	Mine Safety Disclosures	123
PART II
Item 5.	Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities	124
Item 6.	[Reserved]	126
Item 7.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	127
Item 7A.	Quantitative and Qualitative Disclosures About Market Risk	145
Item 8.	Financial Statements and Supplementary Data	146
Item 9.	Changes in and Disagreements with Accountants on Accounting and Financial Disclosure	182
Item 9A.	Controls and Procedures	182
Item 9B.	Other Information	184
Item 9C.	Disclosure Regarding Foreign Jurisdictions that Prevent Inspections	184
PART III
Item 10.	Directors, Executive Officers and Corporate Governance	185
Item 11.	Executive Compensation	185
Item 12.	Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters	185
Item 13.	Certain Relationships and Related Transactions and Director Independence	185
Item 14.	Principal Accountant Fees and Services	185
PART IV
Item 15.	Exhibits and Financial Statement Schedules	186
	Signatures	190

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.

About this filing

Table of Contents